Press releases
-
-
-
-
-
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets
-
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
-
-
-
-
-
-
-
-
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
-
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
-
-
-
Internal link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
-
Internal link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
-
Internal link ProQR Announces Highlights from Analyst Event
-
Internal link ProQR to Webcast Virtual Analyst Event on November 18
-
-
-
-